Nicholas F Evageliou
Overview
Explore the profile of Nicholas F Evageliou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fischer K, Mittal S, Long C, Duffy K, Kalish J, Evageliou N, et al.
Urology
. 2021 Feb;
154:271-274.
PMID: 33581236
An identifiable genetic malformation or predisposition syndrome is present in 18% of Wilms tumor cases. Given this, children with conditions associated with a greater than 1% risk of developing Wilms...
2.
Evageliou N, Haber M, Vu A, Laetsch T, Murray J, Gamble L, et al.
Clin Cancer Res
. 2016 Mar;
22(17):4391-404.
PMID: 27012811
Purpose: Deregulated MYC drives oncogenesis in many tissues yet direct pharmacologic inhibition has proven difficult. MYC coordinately regulates polyamine homeostasis as these essential cations support MYC functions, and drugs that...
3.
Ruebner R, Copelovitch L, Evageliou N, Denburg M, Belasco J, Kaplan B
Pediatr Nephrol
. 2013 Dec;
29(5):863-9.
PMID: 24310825
Background: Tyrosine kinase (TK) inhibitors are increasingly being used to treat a variety of pediatric malignancies. Reports in adult patients describe a range of effects of TK inhibitors on the...
4.
Evageliou N, Hogarty M
Clin Cancer Res
. 2009 Oct;
15(19):5956-61.
PMID: 19789308
MYC genes are deregulated in a plurality of human cancers. Through direct and indirect mechanisms, the MYC network regulates the expression of > 15% of the human genome, including both...
5.
Hogarty M, Norris M, Davis K, Liu X, Evageliou N, Hayes C, et al.
Cancer Res
. 2008 Dec;
68(23):9735-45.
PMID: 19047152
Neuroblastoma is a frequently lethal childhood tumor in which MYC gene deregulation, commonly as MYCN amplification, portends poor outcome. Identifying the requisite biopathways downstream of MYC may provide therapeutic opportunities....